AIV Logo AIV Assistant

Loading...

 Logo CSL Limited - CSL.AX Open CSL Limited in new tab

180.66
P/E
22.32
EPS
9.52
P/B
5.32
ROE
0.15
Beta
0.26

180.6550

180.655

Daily: -0.29%
Key Metrics

Earnings date: Feb. 8, 2026

P/E: 22.32

EPS: 9.52

Book Value: 39.93

Price to Book: 5.32

Debt/Equity: 53.71

% Insiders: 0.000%

Growth

Revenue Growth: 0.05%

Earnings Growth: 0.33%

Estimates

Forward P/E: 17.88

Forward EPS: 11.88

 Logo About CSL Limited - (CSL.AX)

Country: Australia

Sector: Health Care

CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. This segment also offers therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. It also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

Dividends

CSL Limited
Oct 03, 2025 Paid
Dividend
AUD
CSL Limited
Apr 09, 2025 Paid
Dividend
AUD

Historical Split Corporate Actions

Trades
My Trades
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion